An Unusual Case of Colon Perforation With Multiple Transmural Ulcers After Use of Polmacoxib and Everolimus in a Metastatic Breast Cancer Patient
Annals of Coloproctology
; : 120-124, 2021.
Article
em En
| WPRIM
| ID: wpr-913391
Biblioteca responsável:
WPRO
ABSTRACT
Everolimus (Afinitor) is an inhibitor of mammalian target of rapamycin. Polmacoxib (Acelex) is a nonsteroidal anti-inflammatory drug that belongs to the cyclooxygenase-2 (COX-2) inhibitor family and is mainly used for treatment of arthritis. Intestinal perforation has not been reported previously as a complication of everolimus, and perforation of the lower intestinal tract caused by a selective COX-2 inhibitor is extremely rare. We present here a case of colon perforation that occurred after use of polmacoxib in a metastatic breast cancer patient who had been treated with everolimus for the preceding six months.
Texto completo:
1
Índice:
WPRIM
Idioma:
En
Revista:
Annals of Coloproctology
Ano de publicação:
2021
Tipo de documento:
Article